– Lorient Capital announced the final close of Lorient Healthcare Fund III with $500 million in total commitments, exceeding its initial $350 million target.
– The fund closed on June 30th and was oversubscribed.
– Lorient invests in founder-led, middle-market healthcare companies, providing sector expertise, hands-on operational support, and a repeatable scaling approach.
– The firm focuses on improving clinical outcomes, workforce efficiency, and access to care across the U.S.
– “Fund III represents a major step forward in our mission to support companies working to improve the healthcare system and create long-term, sustainable value,” said David Berman and Jordan Broome, Co-Managing Partners at Lorient Capital.
– Lorient targets control-oriented investments in healthcare subsectors including:
Consumer-directed healthcare
Post-acute care
Behavioral health
Provider enablement
Tech-enabled services
– Backed companies work to:
Advance care quality
Expand access in underserved and rural areas
Address workforce shortages
Integrate care for vulnerable populations
Support the shift to value-based care
– One of Lorient’s five core operational domains is quality, which is “actively managed and measured in partnership with clinical leaders using the firm’s proprietary tools and operating approach.”
– Since its founding, Lorient has completed 20 platform investments and 75+ add-on acquisitions, with nine successful exits.
– At the heart of its operational model is Morpheus, Lorient’s proprietary technology platform that consolidates fragmented data into real-time, actionable insights.
– More than a reporting tool, Morpheus integrates with a company’s workflow to benchmark performance, identify gaps, and align operations with strategy.
– With Fund III, Lorient aims to continue backing high-quality management teams and scaling mission-driven healthcare businesses through its disciplined, operations-led strategy.
